Medtronic’s Reactive ATP therapy shows benefits in real-world study

Medtronic has announced the findings of a real-world study that demonstrates the benefits of its Reactive ATP atrial-based antitachycardia pacing therapy.

The analysis of nearly 8,800 patients assessed pacemaker, implantable cardioverter defibrillator and cardiac resynchronisation therapy device data from subjects monitored using the Medtronic CareLink remote monitoring system.

Reactive ATP therapy was associated with a significant decrease in atrial fibrillation events compared to a matched control group, with Reactive ATP patients experiencing a 38 percent reduction in persistent atrial fibrillation events, regardless of patient age, sex or device type.

Dr Rob Kowal, vice-president and chief medical officer of Medtronic's cardiac rhythm and heart failure division, said: "Physicians have been asking how the CareLink Network data can be leveraged to gain real-world insights into the benefits of our therapies. This study does exactly that."

Reactive ATP is an advanced, painless pacing therapy incorporated into Medtronic medical devices that repeatedly sends pacing pulses to the atria during abnormally fast rhythms to restore the heart's normal rhythm.

It has previously been shown to significantly slow atrial fibrillation disease progression, reduce rates of hospitalisation and deliver cost savings.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.